Evidence map›Paper›PMID 27814025›Full record

ReviewAnnual review of pharmacology and toxicology2017

Stem Cell Extracellular Vesicles: Extended Messages of Regeneration.

Milad Riazifar, Egest J Pone, Jan Lötvall, Weian Zhao

Open access · hybridAbstract readReview
In one paragraph

Review in Annual review of pharmacology and toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 3 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 3 syntheses or guidelines pooled it, 342 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Milad RiazifarDepartment of Pharmaceutical Sciences, University of California, Irvine, California 92697; email: weianz@uci.edu.
Egest J PoneDepartment of Pharmaceutical Sciences, University of California, Irvine, California 92697; email: weianz@uci.edu.
Jan LötvallKrefting Research Centre, Institute of Medicine, The Sahlgrenska Academy, Göteborg University, SE-405 30 Göteborg, Sweden.
Weian ZhaoDepartment of Pharmaceutical Sciences, University of California, Irvine, California 92697; email: weianz@uci.edu.
University of California, Irvine · USEdwards Lifesciences (United States) · USUniversity of Gothenburg · SE

Funding

Training Program in Stem Cell Translational Medicine for Neurological DisordersT32NS082174 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI PETER John DONOVAN, Leslie Michels Thompson · 2013 to 2026
$3.3M
Mechano-sensing stem cells to study, detect and treat cancer metastasesDP2CA195763 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZHAO, WEIAN · 2014 to 2014
$2.3M
NCI NIH HHS DP2 CA195763NINDS NIH HHS T32 NS082174
6 · The paper itself

Abstract

Stem cells are critical to maintaining steady-state organ homeostasis and regenerating injured tissues. Recent intriguing reports implicate extracellular vesicles (EVs) as carriers for the distribution of morphogens and growth and differentiation factors from tissue parenchymal cells to stem cells, and conversely, stem cell-derived EVs carrying certain proteins and nucleic acids can support healing of injured tissues. We describe approaches to make use of engineered EVs as technology platforms in therapeutics and diagnostics in the context of stem cells. For some regenerative therapies, natural and engineered EVs from stem cells may be superior to single-molecule drugs, biologics, whole cells, and synthetic liposome or nanoparticle formulations because of the ease of bioengineering with multiple factors while retaining superior biocompatibility and biostability and posing fewer risks for abnormal differentiation or neoplastic transformation. Finally, we provide an overview of current challenges and future directions of EVs as potential therapeutic alternatives to cells for clinical applications.

Indexed as

AnimalsBioengineeringCell DifferentiationExosomesExtracellular VesiclesHumansNanoparticlesRegenerationStem Cellsbioengineeringdrug deliveryexosomesextracellular vesiclesmicrovesiclesstem cells

Identifiers

PMID27814025
PMCPMC5360275
OpenAlexW2506498379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.